

Fragrance-Free Formulation

ReFissa[®]
Tretinoin Cream, USP (Emollient) 0.05%



The Fine Wrinkles Retinoid

Unlike acne retinoids prescribed for adolescents who often have oily skin, ReFissa is specially formulated for dryer, more sensitive adult skin. And it's the only prescription retinoid that has it all: **0.05% strength, emollient base, and fragrance free formulation.**

Compare Prescription Retinoids and See for Yourself

Class/ Drug Name	Indicated for Fine Wrinkles	Indicated for Hyper-pigmentation	Indicated for Tactile Roughness	Emollient Base	0.05% Concentration	Fragrance Free	Formulated for Normal to Dry Skin
WRINKLE RETINOIDS							
<i>ReFissa</i> .05%							
Renova® .02%	X						
Avage® .1%	X	X				X	
ACNE RETINOIDS							
Atralin® Gel					X	X	
Differin®						X	
Retin-A Micro®					X	X	
Retin-A®					X	X	
Note: Renova .05% is not currently available							

ReFissa 0.05% is indicated for mitigation (palliation) of fine facial wrinkles, mottled hyperpigmentation and tactile roughness in patients who use a comprehensive skin care and sunlight avoidance program (including sunscreen).

ReFissa does not eliminate wrinkles, repair sun damaged skin, reverse photoaging or restore more youthful or younger skin.

Do not use if the patient is taking drugs known to be photosensitizers, pregnant, attempting pregnancy, or nursing. ReFissa, early in treatment, may cause redness, itching, burning, stinging and peeling. If the degree of irritation warrants, patient should be advised to use less medication and decrease the frequency of application. If still significant, patient should be advised to discontinue use.

Please see adjacent full Prescribing Information.

References: 1. Data on file. Sunevia Medical, Inc. 2. Renova prescribing information. Los Angeles, CA: OrthoNeutrogena; 2006. 3. Avage prescribing information. Irvine, CA: Allergan, Inc; 2004. 4. Tazorac prescribing information. Irvine, CA: Allergan, Inc; 2008. 5. Differin prescribing information. Fort Worth, TX: Galderma Laboratories, LP; 2003. 6. Retin-A Micro prescribing information. OrthoNeutrogena; Skillman, NJ: 2002. 7. Retin A prescribing information. Skillman, NJ: OrthoNeutrogena; 2001.

Avage® and Tazora®c are registered trademarks of Allergan, Inc. Differin® is a registered trademark of Galderma Laboratories, LP. Renova®, Retin-A® and Retin-A Micro® are registered trademarks of OrthoNeutrogena, a Division of Ortho-McNeil Pharmaceuticals, Inc.

ReFissa is a registered trademark of Sunevia Medical, Inc.
© 2013 Sunevia Medical, Inc. All rights reserved
SM 1321-41 REV00

